Ebglyss (lebrikizumab-lbkz) NDC 0002-7797

NDC codes

FDA NDC Directory

Product NDC (as listed)0002-7797Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00002-7797Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0002-7797-11	00002779711	1 SYRINGE in 1 CARTON (0002-7797-11) / 2 mL in 1 SYRINGE (0002-7797-01)Marketed from Sep 13, 2024
0002-7797-61	00002779761	1 SYRINGE in 1 CARTON (0002-7797-61) / 2 mL in 1 SYRINGEMarketed from Sep 13, 2024 · Sample package

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ebglyss
Generic name (nonproprietary): lebrikizumab-lbkz
Active ingredients: Lebrikizumab — 250 mg/2mL
Dosage form: Injection, Solution
Route: Subcutaneous
Labeler: Eli Lilly and Company
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761306
Marketing start: Sep 13, 2024
Listing expires: Dec 31, 2027
Other FDA classes: Interleukin-13 Antagonists (Mechanism)
Identifiers: Product ID 0002-7797_361eb12f-8b25-4174-a653-5b857e6abd03SPL ID 361eb12f-8b25-4174-a653-5b857e6abd03SPL set ID 7a774ea2-acde-4aaa-9a8f-ccba5a5b1d5fRxCUI 2693784, 2693791, 2693903, 2693907UNII U9JLP7V031
Pharmacologic class: Interleukin-13 Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N400002779711 followed by a unit qualifier and the quantity

Package 00002-7797-11. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 9, 2026.

Indications (excerpt from the label)

EBGLYSS is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids. EBGLYSS ® is an interleukin-13 antagonist indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without to…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under BLA 761306

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 761306
Product	Strength	Form · route	Labeler	Product NDC
Ebglysslebrikizumab-lbkz	Lebrikizumab 250 mg/2mL	Injection, SolutionSubcutaneous	Eli Lilly and Company	0002-7772